Drugs / CITY-FXI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07430397 | Jan 2026 → Aug 2027 expected | thrombophilia due to activated protein C resistance | City Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CITY-FXI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07430397 ↗ |
| Modality | Small interfering RNA (siRNA) | “a FXI Targeting siRNA” NCT07430397 ↗ |
| Route | Subcutaneous | “Administered Subcutaneously” NCT07430397 ↗ |